CD3xCD123 BsAB have clinical impact potential in MM as they may help treatment outcomes by blocking immune evasion via depletion of CD123+ MDSC and by reducing the drug-resistant tumor load via CTL-mediated MHC-independent destruction of MM stem cells. Here, HLA-C is linked to Miyoshi myopathy.